Information  X 
Enter a valid email address

TempletonEmerg.Mkt. (TEM)

  Print      Mail a friend       Annual reports

Friday 14 September, 2018

TempletonEmerg.Mkt.

Transaction in Own Shares

RNS Number : 8826A
Templeton Emerging Markets IT PLC
14 September 2018
 

Stock Exchange Announcement

Templeton Emerging Markets Investment Trust PLC ("the Company")

Transaction in Own Shares

Legal Entity Identifier 5493002NMTB70RZBXO96

 

 

The Company announces that, on 14 September 2018, it purchased into Treasury 76,939 ordinary shares of 25 pence each in the Company ("Shares") at a price of 690.56 pence per Share. Following this transaction, the Company holds 19,108,380 Shares in Treasury. The Company will only re-issue shares held in Treasury at a premium to net asset value.

 

Following this transaction, the Company's share capital consists of 258,810,573 Shares in issue and 19,108,380 Shares held in Treasury. Therefore, the total number of voting rights in the Company is 258,810,573. In order to protect the interests of existing shareholders, shares held in treasury will only be reissued at a price above the prevailing NAV per share at the time of reissue.

 

This figure (258,810,573) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with DTR 5.5.1, the 19,108,380 Shares held in Treasury as a percentage of the total voting rights in the Company is 7.38%. Shares held in Treasury are excluded from the total voting rights figure.  

 

For information please contact Winterflood (Corporate Broker) Neil Langford on + 44 (0) 20 3100 0160.

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
POSLLFIRASISLIT

a d v e r t i s e m e n t